Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma

Abstract

Stranzenbach et al. propose alternate dosing regimens of brentuximab vedotin (BV) for CD30+ cutaneous T-cell lymphomas (CTCLs) such as mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL).¹ They emphasize that lower doses or less frequent dosing schedules for CTCL may be equally effective while limiting adverse events.

The authors indicate that CTCLs may require less aggressive therapy than systemic lymphomas such as systemic ALCL (sALCL) or Hodgkin lymphoma (HL).

This article is protected by copyright. All rights reserved.

http://ift.tt/2xn80nO